|
Since its foundation in 1890, Santen Pharmaceutical Co., Ltd. has contributed to the protection and improvement of people's eyesight and health. Santen's integrated operations extend from research and development to production and sales of prescription and over-the-counter pharmaceuticals.
Today, Santen specializes in original ophthalmic and anti-rheumatic pharmaceuticals as it works to create superior pharmaceuticals for all types of ophthalmic disorders and offer information that meets clinical needs. As a result, Santen leads Japan's market for prescription ophthalmics, which represent over 80 percent of Company sales.
With marketing and development bases in Japan, the United States and Europe, backed by first-rate R&D capabilities, Santen aims to increase corporate value to become a world-class company that delivers unique products to patients worldwide.
|
|
Sales By Business
|
(Net Sales: 110,594 million yen)
Percentage of consolidated net sales by business segment for the year ended March 31, 2010
|
|
Summary by Business Segment
|
|
Prescription Pharmaceuticals
|
[Prescription Ophthalmics]
Santen leads the Japanese market for prescription ophthalmics with a share
of nearly 40 percent. We offer treatments for a wide range of ophthalmic
disorders and covers ophthalmologists nationwide with the largest number of
medical
representatives in Japan. We also have overseas bases in the United States,
Europe and Asian
countries for the development, production and sale of ophthalmic pharmaceuticals.
[Anti-rheumatic Pharmaceuticals]
Santen's second largest business area is anti-rheumatic pharmaceuticals,
and we provide three disease modifying anti-rheumatic drugs (DMARDs) to healthcare
institutions throughout Japan for the treatment of rheumatoid arthritis.
Furthermore, we are strengthening our research and development efforts to
develop new anti-rheumatic drugs to succeed these two products.
|
Over-the-Counter (OTC) Pharmaceuticals
|
Since the launch of Daigaku Eye Drops in 1899, Santen has been committed to the development, production and marketing of superior OTC ophthalmic products, with a focus on basic treatment and eye disease prevention. A consistent emphasis on creativity and innovation, such as introducing Japan's first plastic eye drop container in 1962, highlights Santen's determination to put numerous innovative ideas into practice. Major OTC products include Sante FX Neo , the Sante de u series and the Sante 40 series, which have been well-recognized among Japanese consumers for many years.
|
Medical Devices
|
Santen participates in the ophthalmic devices market as an expert in the field of ophthalmology, and the ability to provide products and services to medical institutions in addition to pharmaceuticals illustrates our strength. Our main products include phacoemulsification machines for cataract surgery, intraocular lenses and surgical instruments. In November 2001, Santen strengthened its ability to develop intraocular lenses by acquiring the U.S. company Advanced Vision Science, Inc., which is involved in the research, development, production and marketing of intraocular lenses.
|
Back to top |
|
|
